XPARBOI
Market cap482mUSD
Dec 24, Last price
26.70EUR
1D
3.09%
1Q
-16.43%
Jan 2017
-68.28%
Name
Boiron SA
Chart & Performance
Profile
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 493,248 -7.67% | 534,239 17.36% | 455,201 -11.37% | |||||||
Cost of revenue | 373,757 | 470,314 | 407,106 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 119,491 | 63,925 | 48,095 | |||||||
NOPBT Margin | 24.23% | 11.97% | 10.57% | |||||||
Operating Taxes | 12,911 | 13,685 | 16,288 | |||||||
Tax Rate | 10.80% | 21.41% | 33.87% | |||||||
NOPAT | 106,580 | 50,240 | 31,807 | |||||||
Net income | 35,827 -19.80% | 44,673 56.44% | 28,556 8.95% | |||||||
Dividends | (198,969) | (16,502) | (16,643) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (122) | (11,539) | (4,744) | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 7,057 | 5,428 | 4,887 | |||||||
Long-term debt | 16,662 | 16,738 | 7,719 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 65,727 | 67,396 | 78,344 | |||||||
Net debt | (65,853) | (234,916) | (226,271) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 45,491 | 60,099 | 33,879 | |||||||
CAPEX | (9,858) | (18,591) | (20,418) | |||||||
Cash from investing activities | (22,926) | (15,277) | (11,921) | |||||||
Cash from financing activities | (198,413) | (28,986) | (22,557) | |||||||
FCF | 96,005 | 46,555 | 11,790 | |||||||
Balance | ||||||||||
Cash | 74,044 | 250,945 | 234,504 | |||||||
Long term investments | 15,528 | 6,137 | 4,373 | |||||||
Excess cash | 64,910 | 230,370 | 216,117 | |||||||
Stockholders' equity | 319,015 | 484,443 | 453,185 | |||||||
Invested Capital | 406,019 | 409,251 | 399,904 | |||||||
ROIC | 26.15% | 12.42% | 8.00% | |||||||
ROCE | 25.37% | 9.99% | 7.81% | |||||||
EV | ||||||||||
Common stock shares outstanding | 17,362 | 17,389 | 17,516 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 145,116 | 95,753 | 81,466 | |||||||
EV/EBITDA | ||||||||||
Interest | 1,191 | 1,537 | 537 | |||||||
Interest/NOPBT | 1.00% | 2.40% | 1.12% |